An unexpired patent currently prevents the manufacturing of any generic Brilinta (ticagrelor) drugs. This patent is scheduled to expire in July 2018, which would be the earliest date that generic versions could become available. However, lawsuits or other patents for new uses of the drug may delay this process.
Brilinta™ (ticagrelor) is a prescription antiplatelet medication. It helps to prevent harmful blood clots from forming in people who have been hospitalized with chest pain or have had a certain type of heart attack. These conditions are often known as acute coronary syndrome (ACS).
Brilinta is used in combination with aspirin to reduce the risk of future heart attacks, strokes, or blood clots in a stent (a tube placed in an artery of the heart during an angioplasty procedure).
This medication is manufactured by AstraZeneca LP. There are no generic versions of Brilinta available at this time.
The first patent for Brilinta is currently set to expire in 2018. This is the earliest predictable date that a generic version could become available. However, other circumstances could come up to extend or shorten the exclusivity period. This could include such things as lawsuits or other patents for specific Brilinta uses. It is usually quite difficult to predict when exactly a generic version of any medication may become available.
No -- ticagrelor is the active ingredient in Brilinta but is not a generic version of it. What can be confusing is that the active ingredient of any drug is often referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.